India Tightens Regulatory Framework for Gene and Stem Cell Therapies to Ensure Safety and Innovation

The Indian government is moving towards a stringent regulatory environment for gene and stem cell therapies, reflecting the rapidly evolving biotech landscape and public health priorities. The Indian Council of Medical Research (ICMR) and Central Drugs Standard Control Organization (CDSCO) are revising guidelines to emphasize safety, ethical conduct, and expedited approvals.

 

Stem cell therapies are allowed only under strictly controlled clinical trials, with commercial use prohibited due to earlier malpractice cases. Gene therapy development follows a detailed pathway involving several layers of governance, including Institutional Bio Safety Committees, Review Committee on Genetic Manipulation, and Gene Therapy Advisory Evaluation Committee for clinical trial permissions. The government aims to simplify approval processes while maintaining thorough scientific and ethical scrutiny.

 

India's support for innovation is visible through initiatives under the “Make in India” program, focusing on domestic manufacturing of gene therapy and associated biotech products, including indigenous CAR-T therapies. Streamlining regulatory pathways is expected to encourage investments and collaborations, positioning India as a leading player in advanced therapeutics.

 

Important Points:

Sources: Indian Council of Medical Research (ICMR) Guidelines, CDSCO Notifications, Department of Biotechnology, Financial Express, Science Direct.